Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04818216 · ClinicalTrials.gov registry record · Phase 2
Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection
A Phase 2 study of Acute Kidney Injury and SARS CoV 2 Infection, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 4
- Study locations
NCT04818216 is a Phase 2 study of Acute Kidney Injury and SARS CoV 2 Infection that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 28 participants, below the 2,331-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT04818216, a Phase 2 study of Acute Kidney Injury and SARS CoV 2 Infection, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 4
- Study locations
Study Summary
An interventional clinical trial using oral nicotinamide riboside (NR) in hospitalized patients with COVID-19 infection and acute kidney injury to determine the effect of NR on whole blood nicotinamide adenine dinucleotide (NAD+) levels and to evaluate safety of the use of NR.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Nicotinamide riboside
Study Locations (4)
Texas
- The University of Texas Health Science Center at San Antonio - San Antonio
- University Health Systems - San Antonio
New York
- Icahn School of Medicine at Mount Sinai - New York
Washington
- Harborview Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2021-06-11 |
| Est. Completion | 2022-01-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04818216
The ClinicalTrials.gov registry entry for NCT04818216 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,331-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (99% lower). The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Acute Kidney Injury appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04818216 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Texas, New York, Washington.
Frequently Asked Questions
What is clinical trial NCT04818216 about?
NCT04818216 is a clinical study titled "Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection". An interventional clinical trial using oral nicotinamide riboside (NR) in hospitalized patients with COVID-19 infection and acute kidney injury to determine the effect of NR on whole blood nicotinamide adenine dinucleotide (NAD+) levels and to evaluate safety of the use of NR.
What is the current status of trial NCT04818216?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2021-06-11. Estimated completion is 2022-01-03.
What conditions does trial NCT04818216 study?
This clinical trial studies the following conditions: Acute Kidney Injury, SARS CoV 2 Infection.
What interventions are being tested in trial NCT04818216?
The interventions under investigation include: Placebo (DRUG), Nicotinamide riboside (DRUG).
Who is sponsoring clinical trial NCT04818216?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04818216 being conducted?
This trial has 4 study locations across New York, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome
RECRUITING · Phase 2
-
Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial
RECRUITING · Phase 2
-
Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial)
RECRUITING · Phase 2
-
Comparison of Early Proton Pump Inhibitor Initiation Versus Usual Care on Acute Kidney Injury in Hemorrhagic Shock Patients
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.